Bank of New York Mellon Corp Lowers Position in Smith & Nephew plc (NYSE:SNN)

Bank of New York Mellon Corp lessened its holdings in Smith & Nephew plc (NYSE:SNN - Free Report) by 7.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 177,483 shares of the medical equipment provider's stock after selling 15,147 shares during the period. Bank of New York Mellon Corp's holdings in Smith & Nephew were worth $4,363,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of SNN. Principal Securities Inc. increased its position in Smith & Nephew by 87.6% during the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock valued at $36,000 after acquiring an additional 691 shares during the last quarter. R Squared Ltd bought a new position in Smith & Nephew during the fourth quarter valued at $41,000. Hara Capital LLC increased its position in Smith & Nephew by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after acquiring an additional 1,957 shares during the last quarter. GAMMA Investing LLC increased its position in Smith & Nephew by 31.8% during the fourth quarter. GAMMA Investing LLC now owns 2,975 shares of the medical equipment provider's stock valued at $73,000 after acquiring an additional 718 shares during the last quarter. Finally, Blue Trust Inc. increased its position in Smith & Nephew by 26.0% during the fourth quarter. Blue Trust Inc. now owns 5,871 shares of the medical equipment provider's stock valued at $144,000 after acquiring an additional 1,213 shares during the last quarter. Institutional investors own 25.64% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SNN. Canaccord Genuity Group reiterated a "hold" rating and set a $27.00 price objective on shares of Smith & Nephew in a research report on Monday, March 17th. StockNews.com raised shares of Smith & Nephew from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, February 26th. Finally, UBS Group lowered shares of Smith & Nephew from a "buy" rating to a "neutral" rating in a research note on Wednesday, March 12th. Four investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $27.00.

Smith & Nephew Trading Down 1.3 %

Shares of SNN traded down $0.38 during trading hours on Friday, reaching $28.08. 443,227 shares of the company traded hands, compared to its average volume of 817,297. The firm has a market cap of $12.27 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 1.26 and a beta of 0.83. Smith & Nephew plc has a 12-month low of $23.65 and a 12-month high of $31.72. The company has a current ratio of 2.51, a quick ratio of 1.11 and a debt-to-equity ratio of 0.63. The stock's fifty day moving average price is $26.77 and its 200 day moving average price is $27.09.

Smith & Nephew Increases Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Wednesday, May 28th. Investors of record on Friday, March 28th will be paid a $0.447 dividend. The ex-dividend date is Friday, March 28th. This is a positive change from Smith & Nephew's previous semi-annual dividend of $0.29. This represents a yield of 2.5%. Smith & Nephew's dividend payout ratio is 41.20%.

About Smith & Nephew

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.